Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701791 | Journal of Thoracic Oncology | 2016 | 48 Pages |
Abstract
Both disease control (PR plus stable disease status) and landmark progression-free survival were correlated with OS, with the longer interval landmark PFS being the best predictor of survival in patients with NSCLC treated with anti-PD-1/PD-L1 antibodies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Takehito MD, PhD, Keita PhD, Joseph M. PhD, Erin M. MD, Gregory A. MD, Peter G. MD, Satoshi PhD, David P. MD, PhD,